Literature DB >> 1538161

Tumor necrosis factor in septicemic melioidosis.

Y Suputtamongkol1, D Kwiatkowski, D A Dance, W Chaowagul, N J White.   

Abstract

Plasma concentrations of the cytokine tumor necrosis factor (TNF) were measured serially in 91 patients suspected of having septicemic melioidosis. This was confirmed in 55. TNF was detectable in admission plasma (TNF0) in 3 of 15 survivors of septicemic melioidosis and 21 of 26 fatal cases (P less than .001). The median (range) TNF0 concentration in melioidosis patients who died was 96 (1-4774) pg/ml, and the median time to death was 25 (5-672) h. TNF0 was inversely correlated with the lowest mean arterial pressure in the succeeding 12 h (Spearman's rank correlation coefficient = .67, 2P less than .001). Three patterns of TNF plasma concentrations were evident: relatively constant values between 100 and 500 pg/ml (n = 7), high admission concentrations (greater than 1000 pg/ml) associated with early death (n = 4), and an apparent pulse release after treatment, with peak values greater than 1000 pg/ml, which then declined with a mean (SD) apparent half-time of 131 (50) min (n = 8). Further studies are necessary to determine whether TNF contributes to lethality in melioidosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538161     DOI: 10.1093/infdis/165.3.561

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Modified virulence of antibiotic-induced Burkholderia pseudomallei filaments.

Authors:  Kang Chen; Guang Wen Sun; Kim Lee Chua; Yunn-Hwen Gan
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  The CXC chemokines gamma interferon (IFN-gamma)-inducible protein 10 and monokine induced by IFN-gamma are released during severe melioidosis.

Authors:  F N Lauw; A J Simpson; J M Prins; S J van Deventer; W Chaowagul; N J White; T van der Poll
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

3.  Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei.

Authors:  G C Ulett; N Ketheesan; R G Hirst
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

4.  Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei.

Authors:  Surasakdi Wongratanacheewin; Wannapa Kespichayawattana; Pakamas Intachote; Sathit Pichyangkul; Rasana W Sermswan; Arthur M Krieg; Stitaya Sirisinha
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

5.  CpG-modified plasmid DNA encoding flagellin improves immunogenicity and provides protection against Burkholderia pseudomallei infection in BALB/c mice.

Authors:  Yao-Shen Chen; Yu-Shan Hsiao; Hsi-Hsun Lin; Yin Liu; Ya-Lei Chen
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

6.  Glucose uptake by Listeria monocytogenes Scott A and inhibition by pediocin JD.

Authors:  D P Christensen; R W Hutkins
Journal:  Appl Environ Microbiol       Date:  1994-10       Impact factor: 4.792

7.  Analogous cytokine responses to Burkholderia pseudomallei strains contrasting in virulence correlate with partial cross-protection in immunized mice.

Authors:  Glen C Ulett; Natkunam Ketheesan; Timothy W Clair; Catriona L McElnea; Jodie L Barnes; Robert G Hirst
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei.

Authors:  P Santanirand; V S Harley; D A Dance; B S Drasar; G J Bancroft
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

9.  Evaluation of surrogate animal models of melioidosis.

Authors:  Jonathan Mark Warawa
Journal:  Front Microbiol       Date:  2010-12-29       Impact factor: 5.640

Review 10.  Development of Burkholderia mallei and pseudomallei vaccines.

Authors:  Ediane B Silva; Steven W Dow
Journal:  Front Cell Infect Microbiol       Date:  2013-03-11       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.